Invest in the Future of Diagnostic Solutions
Stay ahead with the latest updates on our breakthroughs, performance, and shareholder news.
The BlinkLab Pipeline
Below you find the latest version of our product pipeline. Any updates on our progress you will read in the news & announcement section.
Studies
Studies
Approval
Authorization
Analyst Coverage
Read independent insights and analysis on our company’s performance, provided by analysts tracking our progress.
January 2025
East Coach Research: Revolutionising Autism and ADHD Diagnosis with AI-Powered Smartphone Technology
October 2024
Lodge Partners sees 430% upside for Blinklab, developer of smartphone autism test
October 2024
Lodge Partners Initiation Research Report BlinkLab Ltd (ASX:BB1) ASD & ADHD
March 2024
Bioshares, Australia’s Independent Biotech Investment Resource, est.1999 – 11
We've been featured in the media
Discover what the press is saying about us. Check out our latest media mentions and see how we’re making an impact.
"For me it's gratifying to apply neuroscience for improving autism diagnosis and care."
Dr. Henk-Jan Boele, co-founder of BlinkLab, leads a team of neuroscientists, medical doctors, and software developers to bring this mission to life. Founded as a Princeton University startup in 2021, BlinkLab went public on the ASX (ASX:BB1) in April 2024 and is now seeking FDA clearance for its first diagnostic product.
Reach out to our investor relations team.
Are you an active shareholder, or looking to become one? We are here for all your inquiries. Using the form your inquiry will be redirected to the investor relations team, getting back to you within a few days. Or, reach out to one of the team members personally.
Thank you!
Your submission has been received!
Meet our team!
Our team combines clinical expertise, scientific rigor, and smart solutions to drive innovation.
.png)
